Industry News

Stempeutics receives US Process Patent for its Novel Stem Cell Drug "Stempeucel®"

  • Posted on: 5 March 2015
  • By: PharmaTutor News

(Business Wire India); Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel®. Stempeucel® will initially be used for the treatment of CLI and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

GSK completes deal with Novartis and capital return £4bn

  • Posted on: 2 March 2015
  • By: PharmaTutor News

GlaxoSmithKline plc (GSK) announces that its three-part transaction with Novartis has completed today. As a result of this transaction, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion; has created a new world-leading Consumer Healthcare joint venture with Novartis in which GSK will have majority control and an equity interest of 63.5%; and has divested its Oncology business for an aggregate cash consideration of $16 billion.

Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets

  • Posted on: 17 February 2015
  • By: PharmaTutor News

-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab)
-- Inflectra provides an alternative, potentially more affordable treatment option for people suffering from severe, debilitating diseases such as rheumatoid arthritis and inflammatory bowel disease while maintaining comparable quality, efficacy and safety to the reference product

GSK acquire vaccine biopharmaceutical company-GlycoVaxyn AG

  • Posted on: 16 February 2015
  • By: PharmaTutor News

GSK has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland and seems to stregthen their vaccine pipeline. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and has now acquired the remaining shares for US $190 million (approximately £124 million) in cash to take full ownership of the company.

U.K. subsidiary of Cipla enters into a joint venture with Cooper Pharma and PHI

  • Posted on: 10 February 2015
  • By: PharmaTutor News

Cipla Ltd., a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it’s wholly owned subsidiary, Cipla (EU) Limited, U.K. has entered into a joint venture (JV) agreement with Cipla’s existing business partners in Morocco – Societe Marocaine De Cooperation Pharmaceutique (“Cooper Pharma”) and The Pharmaceutical Institute (PHI).

Pfizer's Ibrance got accelerated approval from US FDA

  • Posted on: 4 February 2015
  • By: PharmaTutor News

U. S. Food and Drug Administration granted accelerated approval to palbociclib (IBRANCE, Pfizer, Inc.) for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.